Trontinemab
CAS No. 2568868-35-7
Trontinemab( —— )
Catalog No. M37269 CAS No. 2568868-35-7
Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 947 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTrontinemab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.
-
DescriptionTrontinemab is a bispecific and humanized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetBeta Amyloid
-
RecptorBeta Amyloid
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2568868-35-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Hoechst 34580
Hoechst 34580, a cell-permeable fluorescent dye, is used for staining DNA and nuclei.Hoechst 34580 is a good candidate for treating Alzheimer’s disease by inhibiting Aβ formation. 50 μM Aβ42 solutions co-incubated with 100, 25, 12.5, 3.125, 0.78, and 0.1, 0.01 μM Hoechst 34580 at 37 °C for 70 h. Hoechst 34580 can inhibit the aggregation of Aβ42 in a dose-dependent manner.
-
β-Amyloid 29-40
β-Amyloid (29-40) is a fragment of Amyloid-β peptide.Alzheimer's beta amyloid peptide (29-40/42) C-terminal fragments have physical and chemical properties related to those of fusion peptides of viral proteins. The fusion of liposomes can be induced by these peptides in vitro.
-
Lecanemab
Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.
Cart
sales@molnova.com